Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease.
Takahisa GonoKenichi MasuiNaoshi NishinaYasushi KawaguchiAtsushi KawakamiKei IkedaYohei KirinoYumiko SugiyamaYoshinori TaninoTakahiro NunokawaYuko KanekoShinji SatoKatsuaki AsakawaTaro UkichiShinjiro KaiedaTaio NaniwaYutaka OkanoMasataka Kuwananull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
Our findings indicate that an evidence-based risk prediction model using CRP and KL-6 levels combined with anti-MDA-5 antibody status might be useful for predicting prognosis in patients with PM/DM-ILD.